Second U.S. jury finds Bayer’s Roundup caused cancer

(Reuters) – A U.S. jury on Tuesday found Bayer AG’s glyphosate-based Roundup weed killer caused cancer, a blow to the company eight months after another jury issued a $289 million verdict over similar claims in a different case.

FILE PHOTO: Monsanto’s Roundup weedkiller atomizers are displayed for sale at a garden shop near Brussels, Belgium November 27, 2017. REUTERS/Yves Herman/File Photo

Tuesday’s unanimous jury decision in San Francisco federal court, which came after five days of deliberation, was not a finding of Bayer’s liability for the cancer of plaintiff Edwin Hardeman. Liability and damages will be decided by the same jury in a second trial phase beginning on Wednesday.

Bayer, which denies allegations that glyphosate or Roundup cause cancer, in a statement on Tuesday said it was disappointed with the jury’s initial decision. Bayer acquired Monsanto, the longtime maker of Roundup, for $63 billion last year.

“We are confident the evidence in phase two will show that Monsanto’s conduct has been appropriate and the company should not be liable for Mr. Hardeman’s cancer,” the company said.

Glyphosate is the world’s most widely used weed killer. Monsanto’s Roundup was the first glyphosate-based weed killer but is no longer patent-protected and many other versions are now available. Bayer does not provide sales figures for the product.

The case was only the second of some 11,200 Roundup lawsuits to go to trial in the United States. Another California man was awarded $289 million in August after a state court jury found Roundup caused his cancer, sending Bayer shares plunging at the time. That award was later reduced to $78 million and is on appeal.

Bayer had claimed that jury was overly influenced by plaintiffs’ lawyers allegations of corporate misconduct and did not focus on the science.

U.S. District Judge Vince Chhabria called such evidence “a distraction” from the scientific question of whether glyphosate causes cancer. He split the Hardeman case into two phases: one to decide causation, the other to determine Bayer’s potential liability and damages.

Under Chhabria’s order, the second phase would only take place if the jury found Roundup to be a substantial factor in causing Hardeman’s non-Hodgkin’s lymphoma. The jury found that it was on Tuesday.

NOT AN ABERRATION

Carl Tobias, a law professor at the University of Richmond, said Tuesday’s decision showed that the August jury verdict was not an aberration and that the Hardeman case could be an indication of what may happen in future similar cases.

Some legal experts had said Chhabria’s decision was beneficial to Bayer, which says decades of studies and regulatory evaluations have shown the weed killer to be safe for human use.

“We will only really know whether it works for Bayer to isolate scientific issues once we see more trials,” said Adam Zimmerman, a law professor focusing on mass torts at Los Angeles-based Loyola Law School.

Chhabria has scheduled another bellwether trial for May and a third trial is likely to take place this year. All three bellwether cases will be split into causation and liability phases.

The U.S. Environmental Protection Agency, the European Chemicals Agency and other regulators have found that glyphosate is not likely carcinogenic to humans. But the World Health Organization’s cancer arm in 2015 reached a different conclusion, classifying glyphosate as “probably carcinogenic to humans.”

In the trial’s second phase, Hardeman’s lawyers will be allowed to present evidence allegedly showing the company’s efforts to improperly influence scientists, regulators and the public about the safety of Roundup.

Hardeman’s lawyers, Aimee Wagstaff and Jennifer Moore, said they look forward to presenting that evidence to the jury to hold Monsanto accountable.

FILE PHOTO: Logo of Bayer AG is pictured at the annual results news conference of the German drugmaker in Leverkusen, Germany February 27, 2019. REUTERS/Wolfgang Rattay

“Now we can focus on the evidence that Monsanto has not taken a responsible, objective approach to the safety of Roundup,” they said in a statement.

Chhabria is overseeing more than 760 Roundup cases for which Hardeman’s was a so-called bellwether trial intended to help determine the range of damages and define settlement options for the others.

Another Roundup trial is scheduled to begin in California state court in Oakland on March 28, involving a couple who claim Roundup caused their non-Hodgkin’s lymphoma.

Reporting by Jim Christie in San Francisco; Additional reporting and writing by Tina Bellon in New York; Editing by Bill Berkrot

Source

more recommended stories

  • China draws up tighter rules on human gene and embryo trials: Xinhua

    FILE PHOTO: A student at Ayi.

  • Second death in Novartis gene therapy trials under investigation

    (Reuters) – Novartis AG, which this.

  • Judge upholds New York City’s mandatory measles vaccination order

    NEW YORK (Reuters) – A Brooklyn.

  • Dozens of doctors in Appalachia charged in opioid fraud bust

    (Reuters) – Dozens of medical professionals.

  • Germany to launch cannabis farming as Canada’s Aurora, Aphria win tenders

    FRANKFURT (Reuters) – Germany has awarded.

  • Most diabetes apps lack real-time advice on blood sugar management

    (Reuters Health) – Hundreds of smartphone.

  • U.S. measles cases surge nearly 20 percent in early April, CDC says

    (Reuters) – The number of confirmed.

  • Catalent to buy Paragon Bioservices for $1.2 bln – WSJ

    (Reuters) – Drug developer Catalent Inc.

  • Caito Foods recalls fresh cut melon over Salmonella outbreak

    (Reuters) – An Indianapolis food company.

  • FDA pulls up Walmart, Kroger, others for selling tobacco to minors

    FILE PHOTO: A Walmart sign is.

  • Clovis Oncology halts mid-stage bladder cancer trial, shares drop

    (Reuters) – Clovis Oncology Inc said.

  • South Korea WTO appeal succeeds in Japanese Fukushima food dispute

    FILE PHOTO: The World Trade Organization.

  • South Korea court strikes down law criminalizing abortion in landmark ruling

    SEOUL (Reuters) – In a landmark.

  • U.S. charges pummel drugmaker Indivior, hurt Reckitt

    (Reuters) – Indivior Plc lost three-quarters.

  • New York orders mandatory measles vaccinations, blasts misinformation fueling outbreak

    NEW YORK (Reuters) – New York.

  • Zogenix’s seizure drug filing fails to pass U.S. FDA scrutiny

    (Reuters) – The U.S. Food and.

  • China reports first African swine fever outbreak in Tibet

    BEIJING (Reuters) – China’s agriculture ministry.

  • China’s Inner Mongolia reports human infection of H7N9 bird flu virus: Xinhua

    BEIJING (Reuters) – China’s Inner Mongolia.

  • Factbox: Cyclone Idai’s death toll rises to 843, hundreds of thousands displaced

    BEIRA, Mozambique (Reuters) – Hundreds of.

  • CDC investigates E.coli outbreak in several states

    FILE PHOTO: A general view of.

  • Oklahoma drops several claims in opioid case against J&J, Teva

    (Reuters) – Oklahoma’s attorney general on.

  • U.S. House condemns Trump’s courtroom efforts to end Obamacare

    WASHINGTON (Reuters) – Calling it an.

  • Democrats mock Trump over healthcare delay ahead of 2020 election battle

    WASHINGTON (Reuters) – Democrats mocked President.

  • Trump says vote on healthcare can wait until after 2020 election

    (This April 1 story was refiled.

  • Swiss drugmaker Novartis must face doctor kickback suit, U.S. judge rules

    NEW YORK (Reuters) – Novartis AG.

  • First cholera death recorded since cyclone hit Mozambique port, cases double

    A woman walks with her children.

  • Ebola treatment center in Congo reopens after attack

    (Reuters) – An Ebola treatment center.

  • Cholera cases jump to 138 in Mozambique’s Beira after cyclone

    BEIRA, Mozambique (Reuters) – The number.

  • Fresenius Medical Care to pay $231 million to resolve criminal, civil foreign bribery charges

    FILE PHOTO: Samples of products of.

  • Frailty before surgery tied to more complications, higher costs

    (Reuters Health) – Patients who are.

  • U.S. jury says Bayer must pay $80 million to man in Roundup cancer trial

    SAN FRANCISCO/NEW YORK (Reuters) – A.

  • Democrats pounce as Trump administration ratchets up attack on Obamacare

    (Reuters) – Top congressional Democrats on.